Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Bacterial penicillin-binding protein

4

Solute carrier family 22 member 11

4

Solute carrier family 22 member 6

4

Solute carrier family 22 member 8

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1984

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acute bacterial otitis media

4

Bone and joint infections

4

Intra-abdominal infections

4

Lower respiratory tract infections

4

Meningitis

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Hoffman-La Roche

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

FDA UNII

4

EPA CompTox

3

EVMPD

3

MERCK INDEX

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER BETA-LACTAM ANTIBACTERIALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Third-generation cephalosporins

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CEFTRIAXONE

75J73V1629

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier family 22 member 8

Bacterial penicillin-binding protein

Solute carrier family 22 member 6

Solute carrier family 22 member 11

Conditions:

Acute bacterial otitis media

Lower respiratory tract infections

Urinary tract infections

Skin and skin structure infections

Pelvic inflammatory disease

Uncomplicated gonorrhea

Intra-abdominal infections

Bone and joint infections

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both ...

penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

CEFTRIAXONE, (E)-

8596N5F144

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier family 22 member 8

Bacterial penicillin-binding protein

Solute carrier family 22 member 6

Solute carrier family 22 member 11

Conditions:

Acute bacterial otitis media

Lower respiratory tract infections

Urinary tract infections

Skin and skin structure infections

Pelvic inflammatory disease

Uncomplicated gonorrhea

Intra-abdominal infections

Bone and joint infections

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both ...

penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

CEFTRIAXONE SODIUM ANHYDROUS

R598PB148Q

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier family 22 member 8

Bacterial penicillin-binding protein

Solute carrier family 22 member 6

Solute carrier family 22 member 11

Conditions:

Acute bacterial otitis media

Lower respiratory tract infections

Urinary tract infections

Skin and skin structure infections

Pelvic inflammatory disease

Uncomplicated gonorrhea

Intra-abdominal infections

Bone and joint infections

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both ...

penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

CEFTRIAXONE SODIUM

023Z5BR09K

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier family 22 member 8

Bacterial penicillin-binding protein

Solute carrier family 22 member 6

Solute carrier family 22 member 11

Conditions:

Acute bacterial otitis media

Lower respiratory tract infections

Urinary tract infections

Skin and skin structure infections

Pelvic inflammatory disease

Uncomplicated gonorrhea

Intra-abdominal infections

Bone and joint infections

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both ...

penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1